OncoMatch/Clinical Trials/NCT04698564

Utility of Hyperpolarized 13C-pyruvate Metabolic Magnetic Resonance Imaging

Is NCT04698564 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies Hyperpolarized 13C-Pyruvate for prostate cancer.

Phase 2RecruitingUniversity of Maryland, BaltimoreNCT04698564Data as of May 2026

Treatment: Hyperpolarized 13C-Pyruvate — This is a two-tiered pilot study in which there will be no randomization and no placebo treatment. This study will be to perform metabolic magnetic resonance imaging on men suspected to have a prostate cancer to understand if metabolic MRI can be safely performed on this population

Check if I qualify

Extracted eligibility criteria

Cancer type

Prostate Cancer

Structured fields extracted by AI. May contain errors — verify against the official protocol.

US trial sites

University of Maryland Medical Center · Baltimore, Maryland

Showing up to 5 US sites. See all sites on ClinicalTrials.gov →

Could you qualify for this trial?

Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.

Check if I qualify